Talphera reports NEPHRO CRRT trial 75% enrolled, KDIGO 2026 draft guideline backs nafamostat
The company said site activation is complete and enrollment completion is expected by year-end, while cash and investments stood at $17.1 million as of June 30, 2026.
SEC filing